CETUXIMAB IN COMBINATION WITH XELIRI OR XELOX IN FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER

被引：0
|
作者：
Ocvirk, Janja [1 ]
Rebersek, Martina [1 ]
Boc, Marko [1 ]
Mesti, Tanja [1 ]
Moltara, Maja Ebert [1 ]
机构：
[1] Inst Oncol Ljubljana, Ljubljana, Slovenia
来源：
ANNALS OF ONCOLOGY | 2011年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：v96 / v96
页数：1
相关论文
共 50 条
  • [1] Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer
    Moosmann, Nicolas
    Heinemann, Volker
    [J]. CLINICAL COLORECTAL CANCER, 2008, 7 (02) : 110 - 117
  • [2] Efficacy and safety of XELIRI plus cetuximab versus XELOX plus cetuximab in first-line treatment of metastatic colorectal cancer (mCRC)
    Ocvirk, J.
    Boc, M.
    Rebersek, M.
    Mesti, T.
    Ebert, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with RAS wild-type metastatic colorectal cancer
    Zekri, Jamal
    Baghdadi, Mohammed Abbas
    Ibrahim, Refaei Belal
    Meliti, Abdelrazak
    Sobahy, Turki M.
    [J]. ECANCERMEDICALSCIENCE, 2022, 16 : 1 - 16
  • [4] CETUXIMAB FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
    Ubago, R.
    Castillo, M. A.
    Flores, S.
    Rodriguez, R.
    Beltran, C.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A433 - A434
  • [5] Cetuximab for the first-line treatment of metastatic colorectal cancer
    Meads, C.
    Round, J.
    Tubeuf, S.
    Moore, D.
    Pennant, M.
    Baylis, S.
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 1 - 8
  • [6] Cetuximab plus Xeliri versus cetuximab plus xelox as first-line treatment of patients with metastatic colorectal cancer (MCRC): A randomised trial of the German Aid CRC study group
    Heinernann, V
    Fischer, Von Weikersthal L.
    Vehling-Kaiser, U.
    Stauch, M.
    Oruzio, D.
    Schulze, M.
    Hass, H.
    Weiss, J.
    Dietzfelbinger, H.
    Moosmann, N.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 13 - 13
  • [7] Role of cetuximab in first-line treatment of metastatic colorectal cancer
    Miguel Jhonatan Sotelo
    Beatriz García-Paredes
    Carlos Aguado
    Javier Sastre
    Eduardo Díaz-Rubio
    [J]. World Journal of Gastroenterology, 2014, (15) : 4208 - 4219
  • [8] Role of cetuximab in first-line treatment of metastatic colorectal cancer
    Sotelo, Miguel Jhonatan
    Garcia-Paredes, Beatriz
    Aguado, Carlos
    Sastre, Javier
    Diaz-Rubio, Eduardo
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (15) : 4208 - 4219
  • [9] Analysis of the randomized trial of the German AIO CRC study group: Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mCRC)
    Stintzing, S.
    Jung, A.
    Vehling-Kaiser, U.
    Stauch, M.
    Hass, H.
    Dietzfelbinger, H.
    von Weikersthal, Fischer L.
    Moosmann, N.
    Kirchner, T.
    Heinemann, V
    [J]. ONKOLOGIE, 2010, 33 : 226 - 226
  • [10] EFFICACY OF BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY WITH IRINOTECAN AND CAPECITABINE (XELIRI) IN FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
    Ocvirk, J.
    Rebersek, M.
    Boc, M.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 129 - 129
12345